Obreja M - Search Results

1

Diabetes Mellitus-A Risk Factor for Unfavourable Outcome in COVID-19 Patients-The Experience of an Infectious Diseases Regional Hospital.

Miftode E, Miftode L, Coman I, Prepeliuc C, Obreja M, Stămăteanu O, Părângă TG, Leca D, Pleşca CE. Miftode E, et al. Among authors: obreja m. Healthcare (Basel). 2021 Jun 23;9(7):788. doi: 10.3390/healthcare9070788. Healthcare (Basel). 2021. PMID: 34201473 Free PMC article.

2

The Pitfalls of Febrile Jaundice. A Case Report.

Obreja M, Teodor A, Leca D, Ceasovschih A, Miftode E. Obreja M, et al. J Crit Care Med (Targu Mures). 2016 May 9;2(2):93-95. doi: 10.1515/jccm-2016-0013. eCollection 2016 Apr. J Crit Care Med (Targu Mures). 2016. PMID: 29967845 Free PMC article.

3

Heparin-Binding Protein (HBP), Neutrophil Gelatinase-Associated Lipocalin (NGAL) and S100 Calcium-Binding Protein B (S100B) Can Confirm Bacterial Meningitis and Inform Adequate Antibiotic Treatment.

Obreja M, Miftode EG, Stoleriu I, Constantinescu D, Vâță A, Leca D, Cianga CM, Dorneanu OS, Pavel-Tanasa M, Cianga P. Obreja M, et al. Antibiotics (Basel). 2022 Jun 19;11(6):824. doi: 10.3390/antibiotics11060824. Antibiotics (Basel). 2022. PMID: 35740230 Free PMC article.

4

Symptoms, Treatment, and Outcomes of COVID-19 Patients Coinfected with Clostridioides difficile: Single-Center Study from NE Romania during the COVID-19 Pandemic.

Stămăteanu LO, Miftode IL, Pleșca CE, Dorneanu OS, Roșu MF, Miftode ID, Obreja M, Miftode EG. Stămăteanu LO, et al. Among authors: obreja m. Antibiotics (Basel). 2023 Jun 22;12(7):1091. doi: 10.3390/antibiotics12071091. Antibiotics (Basel). 2023. PMID: 37508187 Free PMC article.

5

The Applicability of Chromatographic Retention Modeling on Chiral Stationary Phases in Reverse-Phase Mode: A Case Study for Ezetimibe and Its Impurities.

Ferencz E, Kelemen ÉK, Obreja M, Tóth G, Urkon M, Zöldhegyi A, Sipos E, Szabó ZI. Ferencz E, et al. Among authors: obreja m. Int J Mol Sci. 2023 Nov 8;24(22):16097. doi: 10.3390/ijms242216097. Int J Mol Sci. 2023. PMID: 38003286 Free PMC article.

6

Analytical quality by design-compliant retention modeling for exploring column interchangeabilities in separating ezetimibe and its related substances.

Ferencz E, Zöldhegyi A, Kelemen ÉK, Obreja M, Urkon M, Sipos E, Tóth G, Molnár I, Szabó ZI. Ferencz E, et al. Among authors: obreja m. J Chromatogr A. 2022 Oct 25;1682:463494. doi: 10.1016/j.chroma.2022.463494. Epub 2022 Sep 9. J Chromatogr A. 2022. PMID: 36126559

7

Post-protocol therapy and informative censoring in the CANDOR study - Authors' reply.

Usmani SZ, Li C, Obreja M, Dimopoulos M. Usmani SZ, et al. Among authors: obreja m. Lancet Oncol. 2022 Mar;23(3):e98. doi: 10.1016/S1470-2045(22)00077-8. Lancet Oncol. 2022. PMID: 35240099 No abstract available.

8

Computer-assisted UHPLC method development and optimization for the determination of albendazole and its related substances.

Ferencz E, Kelemen ÉK, Obreja M, Sipos E, Vida S, Urkon M, Szabó ZI. Ferencz E, et al. Among authors: obreja m. J Pharm Biomed Anal. 2021 Sep 5;203:114203. doi: 10.1016/j.jpba.2021.114203. Epub 2021 Jun 11. J Pharm Biomed Anal. 2021. PMID: 34153936

9

Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy.

Quach H, Nooka A, Samoylova O, Venner CP, Kim K, Facon T, Spencer A, Usmani SZ, Grosicki S, Suzuki K, Delimpasi S, Weisel K, Obreja M, Zahlten-Kumeli A, Mateos MV. Quach H, et al. Among authors: obreja m. Br J Haematol. 2021 Aug;194(4):784-788. doi: 10.1111/bjh.17541. Epub 2021 May 28. Br J Haematol. 2021. PMID: 34046887 Clinical Trial. No abstract available.

10

Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma.

Facon T, Niesvizky R, Mateos MV, Siegel D, Rosenbaum C, Bringhen S, Weisel K, Ho PJ, Ludwig H, Kumar S, Wang K, Obreja M, Yang Z, Klippel Z, Mezzi K, Goldrick A, Tekle C, Dimopoulos MA. Facon T, et al. Among authors: obreja m. Blood Adv. 2020 Nov 10;4(21):5449-5459. doi: 10.1182/bloodadvances.2020001965. Blood Adv. 2020. PMID: 33166401 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

27 results

Search Page